Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Pramlintide (Symlin)37 residuesKCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTYEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: Symlin, AC137
A 37-amino-acid hormone that your pancreas stopped making. Pramlintide (Symlin) is the only FDA-approved synthetic analog of human amylin, co-secreted with insulin by beta cells after every meal. In type 1 diabetes, amylin production is essentially zero. In type 2 diabetes, it is severely impaired. Clinical trials confirmed postprandial glucose reductions of 3.4 to 5 mmol/L beyond what insulin alone achieves, with HbA1c drops of 0.2 to 0.6 percent and modest weight loss of 0.5 to 1.6 kg. AstraZeneca discontinued Symlin commercially in October 2025, making remaining specialty pharmacy stock the only access route. The black box warning for severe hypoglycemia in type 1 diabetes (16.8% incidence in the first three months) is not optional reading.
Post-meal glucose spikes that insulin alone can't fix. That is the problem pramlintide was built to solve. Pramlintide acetate (brand name Symlin, CAS 151126-32-8) is a synthetic analog of human amylin, the 37-amino-acid peptide hormone that healthy beta cells co-secrete alongside insulin after each meal. Three proline substitutions at positions 25, 28, and 29 prevent the aggregation and amyloid formation that make native amylin unsuitable as a drug. The FDA granted approval in March 2005, and pramlintide remained the only amylin analog on the market for two decades. It works through three mechanisms that insulin simply cannot replicate: slowing gastric emptying so glucose enters the bloodstream more gradually, suppressing inappropriate postprandial glucagon secretion from alpha cells, and promoting satiety through amylin receptors in the area postrema. The combination flattens post-meal glucose curves in a way that even optimized insulin regimens struggle to match. Hollander and colleagues [1] tracked metabolic outcomes in type 2 diabetes patients using insulin, landing on HbA1c reductions of 0.4 to 0.6 percent with weight loss instead of the gain that insulin monotherapy produces. In type 1 diabetes, Ratner's group [2] confirmed postprandial glucose dropped by 3.4 to 5 mmol/L. Both populations lost 0.5 to 1.6 kg of body weight over the trial period. AstraZeneca pulled Symlin from the market in October 2025 (a commercial decision, not a safety-driven withdrawal or FDA recall). No generic exists. Remaining stock through specialty pharmacies is the only current access. Cagrilintide, the next-generation amylin analog from Novo Nordisk with weekly dosing and the CagriSema combination, is the pipeline replacement. The REDEFINE 1 trial (NEJM June 2025) posted 22.7% mean weight loss. Pramlintide did what it could with the technology of 2005; the field has moved on.
Three proline substitutions at positions 25, 28, and 29 separate pramlintide from native human amylin. Those substitutions prevent aggregation into amyloid fibrils, which is the structural problem that kept amylin itself from ever becoming a drug. Pramlintide binds to amylin receptors, heterodimers of the calcitonin receptor paired with receptor activity-modifying proteins RAMP1, RAMP2, or RAMP3, concentrated in the area postrema and hypothalamus. Receptor activation triggers three distinct effects that work alongside insulin. First, vagal inhibition slows gastric emptying. Food takes longer to reach the small intestine, and glucose enters the bloodstream on a more gradual curve rather than in a postprandial spike. Second, glucagon secretion from pancreatic alpha cells is suppressed after meals. This reduces hepatic glucose output during the exact window when insulin is trying to clear circulating glucose. Third, central nervous system satiety signaling reduces food intake at the meal itself. The glucagon suppression deserves extra attention. It is meal-specific. During hypoglycemia, the counter-regulatory glucagon response remains intact. Pramlintide does not blunt the body's ability to rescue itself from low blood sugar; it only blocks the inappropriate glucagon rise that follows eating. Kong and colleagues confirmed this selectivity in a controlled study [3]. Subcutaneous injection reaches peak plasma concentration in approximately 20 minutes. The 48-minute half-life means each injection covers one meal. That is also why the drug requires three daily injections and why the field invested in cagrilintide: weekly dosing through a longer-acting amylin analog.
FDA-approved amylin analog with strong evidence for postprandial glucose reduction in T1D and T2D as insulin adjunct. HbA1c reduction 0.2–0.6%; postprandial glucose reduction 3.4–5 mmol/L beyond insulin alone. Modest weight loss 0.5–1.6 kg. Multiple phase 3 RCTs support efficacy. Black box warning for severe hypoglycemia in T1D (16.8% incidence in first 0–3 months). No new major clinical trials since 2014 label update: research momentum has shifted to next-gen amylin analogs (cagrilintide, petrelintide).
Symlin FDA Prescribing Information (2014, NDA 021332); Hollander et al. Diabetes Care 1998 (PMID 9614619); Ratner et al. Diabetes Care 2002 (PMID 11979398)
T1D max dose (60 mcg) vs T2D max dose (120 mcg) creates a meaningful safety distinction that can be lost in simplified dosing presentations. No head-to-head trials vs GLP-1 agonists. Drug commercially discontinued Oct 2025: access severely limited. Protein binding (~60%) and key drug interactions (acetaminophen, norgestrel, ampicillin) absent from most summaries.
Community confirms glycemic benefit but adherence is poor. Nausea burden and 3× daily injection frequency on top of existing insulin regimen are the primary barriers. Most reports come from r/diabetes_t1 and diabetes.co.uk. Overall sentiment ~3.0/5.
Science and community agree on the glycemic mechanism and postprandial benefit. They diverge on practicality: clinical trials show statistically significant HbA1c and weight improvements, but real-world adherence is low due to nausea and injection frequency. Notably, community dosing closely mirrors the FDA label (T1D titration, 50% insulin reduction), which is atypical; this is one of the few peptides where off-label community use essentially tracks the approved protocol.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 15mcg | 3x Daily (before major meals) |
| Moderate | 60mcg | 3x Daily (before major meals) |
| Aggressive | 120mcg | 3x Daily (before major meals) |
Symlin ships as a pre-filled solution at 1000 mcg/mL. No lyophilized powder, no reconstitution, no bacteriostatic water. The math for syringe units is straightforward on a U-100 insulin syringe: 15 mcg equals 1.5 units, 30 mcg equals 3 units, 60 mcg equals 6 units, 120 mcg equals 12 units. If you're drawing from a vial rather than a pen (remaining stock varies), confirm the concentration is 1000 mcg/mL before calculating. A wrong concentration assumption creates a proportional dosing error. The thing most people miss: T1D and T2D dose ceilings are different. Type 1 diabetes max is 60 mcg per meal. Type 2 diabetes max is 120 mcg per meal. A T1D patient taking 120 mcg is taking double their approved maximum. Always confirm diabetes type before dosing above 60 mcg. Inject within 15 minutes before a major meal containing at least 250 kcal and 30g of carbohydrates. Skipping a meal after injecting is how hypoglycemia happens when there is no incoming glucose to offset the drug's effects. If you forget a dose, skip it entirely and resume at the next major meal. Never double up.
Continuous therapy: pramlintide is designed for ongoing daily use alongside insulin. There is no cycling protocol. Stopping pramlintide requires re-adjusting insulin doses upward to compensate for the loss of glucagon suppression and gastric emptying effects.
Pramlintide requires no cycling. It is a continuous replacement therapy for an absent (T1D) or deficient (T2D) hormone. No receptor desensitization, no hormonal axis suppression, and no antibody formation evidence requiring off periods. Stopping pramlintide necessitates upward re-adjustment of mealtime insulin to compensate for the loss of glucagon suppression and gastric emptying slowing.
Or use the universal Peptide Calculator for any peptide.
Expected: Postprandial glucose reduction 3.4–5 mmol/L beyond insulin alone; HbA1c reduction 0.2–0.4%; weight loss 0.5–1.6 kg vs insulin-only regimen
Monitor: Monitor blood glucose before each meal and 1, 2, 3 hours post-meal during the first 4 weeks. Highest hypoglycemia risk is within 3 hours of injection.
T1D starts at 15 mcg per meal; T2D starts at 60 mcg per meal. This distinction is a safety boundary, not a suggestion.
Reduce your mealtime rapid-acting insulin dose by 50% on the day you start pramlintide. This is an FDA mandate, not optional. The insulin reduction compensates for the glucose-lowering effects pramlintide adds.
For a 1000 mcg/mL vial: 15 mcg equals 1.5 units, 30 mcg equals 3 units, 60 mcg equals 6 units, 120 mcg equals 12 units.
Inject subcutaneously into the abdomen or thigh within 15 minutes before a major meal. Choose an injection site at least 2 inches away from wherever you plan to inject insulin. Never mix pramlintide and insulin in the same syringe; they are chemically incompatible.
Inject your mealtime insulin separately in the second site.
T1D titration: increase by 15 mcg every 3 to 7 days as tolerated. Target 30 to 60 mcg per meal. If nausea prevents reaching 45 to 60 mcg, 30 mcg is an acceptable maintenance dose. Never exceed 60 mcg.
T2D titration: increase from 60 mcg to 120 mcg after 3 to 7 days if tolerated. If nausea prevents reaching 120 mcg, remain at 60 mcg.
Monitor blood glucose before each meal and at 1, 2, and 3 hours post-injection during the first 4 weeks. The hypoglycemia window extends to 3 hours after each dose.
Storage: refrigerate unopened pens or vials at 2 to 8 degrees Celsius. Once in use, store at room temperature (up to 25 degrees Celsius) or refrigerated for up to 30 days. Never freeze.
Standard insulin syringe needles work.
Required co-administration per FDA label. Pramlintide is never used standalone: it complements but does not replace mealtime insulin. Must reduce insulin dose 50% at initiation.
Administer pramlintide, then insulin in a separate syringe at least 2 inches away. Never mix in same syringe (chemically incompatible).
Common T2D background oral therapy. No documented pharmacokinetic interaction with pramlintide. Frequently co-prescribed as part of standard T2D regimen.
Next-generation amylin analog (once weekly dosing). Not stacked with pramlintide: intended as replacement. CagriSema Phase 3 (REDEFINE 1, NEJM June 2025) achieved 22.7% mean weight loss; Novo Nordisk filed for FDA approval in 2025. Pramlintide is being clinically superseded.
Mechanistically complementary (GLP-1 + amylin pathways). NOT recommended without close monitoring: overlapping GI effects and additive hypoglycemia risk. The evidence-based combination is cagrilintide + semaglutide (CagriSema), not pramlintide + semaglutide.
Both delay carbohydrate absorption: additive effect may cause excessive glucose lowering and severe GI symptoms. FDA label: concurrent use not recommended.
Do not combineAdditive gastric emptying delay. Combined use risks unpredictable and prolonged glucose absorption variability.
Do not combinePramlintide delays gastric emptying, reducing acetaminophen Cmax by 20–29%. Take acetaminophen ≥1 hour before or ≥2 hours after pramlintide injection if rapid absorption is needed. FDA label interaction.
Norgestrel Cmax reduced ~30% when co-administered due to delayed gastric emptying. Take OCP at least 1 hour before pramlintide. FDA label interaction.
Pricing updated 2026-04-09
The black box warning comes first. Pramlintide used with insulin carries a risk of severe hypoglycemia, particularly in type 1 diabetes. The FDA label reports 16.8% incidence of severe hypoglycemia in T1D patients during the first zero to three months of treatment. Severe episodes can occur within three hours of injection. This is not a theoretical risk buried in post-marketing data; it is the reason the prescribing information mandates a 50% mealtime insulin dose reduction at initiation and frequent blood glucose monitoring during the first four weeks. Nausea is the most common side effect and the primary reason patients discontinue. Published trial rates range from 10 to 59% depending on the population and trial design. Community data from r/diabetes_t1 and diabetes.co.uk aligns with the higher end of that range, with 30 to 50% of users describing nausea in the first one to two weeks as "significant enough to consider stopping." It typically peaks during the titration phase and fades by week four to eight for patients who persist. Vomiting affects 6 to 14% of patients across trials. Reduced appetite (2 to 9%) is expected and somewhat intentional; the satiety mechanism works on the area postrema. Headache, abdominal pain, and fatigue occur at low but measurable rates. Injection site reactions (redness, swelling, bruising) show up occasionally. Three daily subcutaneous injections on top of an existing insulin regimen create a lot of injection sites over time. Rotating between the abdomen and thigh helps. Gastroparesis is an absolute contraindication. Pramlintide slows gastric emptying by design. In someone whose stomach already empties too slowly, this creates dangerous glucose unpredictability and severe GI symptoms. The drug interaction profile matters more than most summaries acknowledge. Pramlintide delays gastric emptying enough to reduce acetaminophen peak concentration by 20 to 29%. Norgestrel (oral contraceptive) peak concentration drops roughly 30%. Ampicillin absorption is delayed by about 60 minutes. Any oral medication requiring rapid or predictable absorption needs a timing buffer: take it one hour before or two hours after pramlintide. Pregnancy and breastfeeding: no adequate safety data exists. Amylin receptor effects on fetal development have not been studied. Pediatric patients under 18 are excluded from the approved indication. When to stop and seek medical help: recurrent severe hypoglycemia despite proper insulin reduction, development of gastroparesis symptoms, persistent severe nausea at the lowest dose after adequate titration, or signs of allergic reaction.
Verify Pramlintide (Symlin) dosing and safety with a second opinion
Symlin (pramlintide acetate) was officially discontinued by AstraZeneca in October 2025 (commercial decision, not a safety withdrawal). No FDA-approved generic exists. No commercially documented compounding pharmacy programs identified. Any sourcing outside remaining specialty pharmacy stock carries high risk of product quality, authenticity, and sterility.
| Test | When | Target |
|---|---|---|
| Blood glucose (CGM or fingerstick) | Before each meal and 1, 2, 3 hours post-meal during first 4 weeks of each dose level | Postprandial <10 mmol/L (180 mg/dL); pre-meal 4–7 mmol/L (72–126 mg/dL) |
| HbA1c | Baseline, then every 3 months | <7% for most T1D/T2D patients; individualize per clinical judgment |
| 2-hour postprandial glucose delta | Monthly spot-checks after reaching maintenance dose | — |
| Body weight | Monthly | — |
Detect hypoglycemia within 3 hours of injection: the primary black box warning risk. Critical during titration.
Primary efficacy endpoint. Expect 0.2–0.6% reduction from baseline after 3+ months at maintenance dose.
Primary mechanism of action is postprandial glucose reduction: if the delta is not improving (target: ≥3 mmol/L reduction vs pre-pramlintide baseline), reassess dose and timing.
Secondary outcome: modest weight loss expected (0.5–1.6 kg). Weight gain on pramlintide suggests insulin dose re-optimization is needed.
Starting at the lowest dose (15 mcg for T1D, 60 mcg for T2D). Nausea is most common during this period. Mealtime insulin has been cut by 50%. Blood glucose may run slightly higher as the insulin-pramlintide balance is established. Frequent monitoring required.
Titrating upward every 3-7 days as tolerated. Post-meal glucose spikes begin to flatten noticeably. Nausea typically peaks and then starts to fade. This is the highest-risk window for hypoglycemia: watch for symptoms within 3 hours after injection. Insulin doses are being fine-tuned.
Reaching maintenance dose (30-60 mcg for T1D, 120 mcg for T2D). Postprandial glucose reductions of 3-5 mmol/L become consistent. GI side effects have largely resolved. Mild weight loss of 0.5-1 kg may be noticeable. HbA1c starts to trend downward.
Full glycemic benefit realized. HbA1c reduced by 0.2-0.6% from baseline. Weight stable or slightly decreased compared to insulin-only regimen. Postprandial glucose control is predictable. Insulin doses have been re-optimized.
Long-term maintenance. Glycemic improvements sustained. Weight remains stable or slightly below pre-pramlintide levels. Continued adherence to pre-meal timing is necessary for effectiveness.
Days 1 through 7, Initiation and Insulin Adjustment: You start at the lowest dose (15 mcg for T1D, 60 mcg for T2D) and cut your mealtime insulin by half. Glucose may run slightly higher than usual while the new balance gets established. Nausea is the dominant experience this week and the number one reason people quit early. No significant postprandial benefit yet; this period is about tolerance, not results. Weeks 1 through 4, Titration and Hypoglycemia Watch: Dose increases happen every 3 to 7 days as tolerated. Post-meal glucose spikes begin flattening noticeably. This is the highest-risk window for severe hypoglycemia, with the FDA label reporting 16.8% incidence in T1D patients during the first zero to three months. Nausea typically peaks then starts fading. Users who push through week 1 describe the first real postprandial flatness as genuinely encouraging. Watch for hypoglycemia symptoms within 3 hours of every injection. Weeks 5 through 12, Maintenance Dose and GI Adaptation: You've reached 30 to 60 mcg (T1D) or 120 mcg (T2D). GI side effects have largely resolved. Postprandial glucose reductions of 3 to 5 mmol/L are consistent. Mild weight loss of 0.5 to 1 kg may be visible. Adherent users describe smaller meals feeling adequate, which tracks with the satiety mechanism. The injection routine is habitual by now, though the 3x daily frequency remains the biggest long-term complaint. Months 3 through 6, HbA1c Improvement: Lab work reflects the benefit. HbA1c is down 0.2 to 0.6 percent from baseline. Weight is stable or slightly below where it was on insulin alone. Some T1D users report insulin dose reductions of up to 30%. The postprandial glucose pattern is predictable. Insulin doses have been re-optimized from the initial 50% reduction. Months 6 through 12 and beyond, Long-Term Maintenance: Glycemic improvements hold with continued use. No evidence of tolerance or loss of efficacy over time. Long-term adherent users are self-selected; most who found the injection burden unsustainable have already stopped. Drug availability is now a practical concern following the October 2025 commercial discontinuation.
Starting dose (15 mcg T1D, 60 mcg T2D). Mealtime insulin cut by 50%: glucose may run slightly higher while the new balance is established. No significant postprandial benefit expected yet.
Nausea is the dominant experience in week 1 and the primary dropout driver. Users describe the 50% insulin reduction as counterintuitive. Glucose runs unpredictably during this adjustment phase.
Titrating upward every 3–7 days. Post-meal glucose spikes begin flattening. Highest hypoglycemia risk window (T1D: 16.8% severe hypoglycemia incidence per FDA label in first 0–3 months).
Users who push through week 1 begin noticing postprandial flatness. Nausea fades for most by week 3–4. Hypoglycemia episodes reported, typically from insufficient insulin reduction or smaller-than-planned meals.
Maintenance dose established. GI effects largely resolved. Postprandial glucose reductions of 3–5 mmol/L consistent. Weight may decrease 0.5–1 kg.
Adherent users describe meaningful glycemic improvement. Satiety is frequently noted: smaller meals feel adequate. Injection routine is habitual but 3× daily frequency remains the most-cited long-term complaint.
HbA1c reduced 0.2–0.6% from baseline. Weight stable or slightly reduced vs insulin-only. Postprandial glucose control predictable.
Lab improvements visible at 3-month A1c check. Some report insulin dose reductions of up to 30%. Weight-neutral outcome reported even without explicit weight loss: no insulin-related weight gain.
Sustained HbA1c and postprandial glucose improvements with continued use. No evidence of tolerance or loss of efficacy over time.
Long-term adherent users are self-selected. Primary ongoing complaint is injection burden. Drug availability now an emerging practical concern following Oct 2025 commercial discontinuation.
Source: FDA prescribing information: approximately 48 minutes in healthy subjects (SC administration)
Loading the interactive decay curve.
Pramlintide acetate (Symlin) received FDA approval in March 2005 under NDA 021332 for adjunctive treatment in adults with type 1 or type 2 diabetes who use mealtime insulin and have not achieved adequate glycemic control. It is a prescription-only medication and carries a black box warning for insulin-induced severe hypoglycemia. AstraZeneca commercially discontinued Symlin in October 2025. This was a business decision, not a safety-driven withdrawal or FDA recall. No FDA-approved generic pramlintide exists. No compounding pharmacy programs with documented regulatory oversight have been identified. Remaining product is limited to specialty pharmacy stock with existing lot numbers and expiration dates. WADA status: pramlintide does not appear on the current World Anti-Doping Agency prohibited list. Next-generation replacement: cagrilintide (once-weekly amylin analog) from Novo Nordisk has completed Phase 3 trials as CagriSema and an FDA approval filing is pending. Patients currently on pramlintide should discuss transition planning with their prescriber. This content is for educational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or modifying any medication regimen.
Peptide Schedule Research TeamReviewed Apr 20267 Citations
